Skip to main content

Isomorphic Labs details plans for its $5 billion Series C

19 NOVEMBER 2026·2 MIN READ·5 SOURCES

Isomorphic Labs announced a $5 billion Series C on November 17, 2026, and says it will use the funding to advance its scientific work and proprietary AI. The company says it will scale its drug-design engine and therapeutic-candidate pipeline while developing foundational biology models and moving its first therapeutic programs toward clinical trials.

Key takeaways · 5

  • 01

    Isomorphic Labs announced a $5 billion Series C dated November 17, 2026.

  • 02

    Greenoaks and Sequoia Capital co-led the round, with Alphabet making a significant investment.

  • 03

    The company says it will mature IsoDDE and expand into new biology with advanced models.

  • 04

    Isomorphic Labs reported positive preclinical results in internal oncology and immunology programs and in work with partners.

  • 05

    The company says the funding will support its first therapeutic programs moving toward clinical trials; the evidence does not report that trials have begun.

A large round with broad participation

Isomorphic Labs announced a $5 billion Series C dated November 17, 2026.[1] Greenoaks and Sequoia Capital co-led the financing, while Andreessen Horowitz and several other new investors joined.[1] Alphabet also made a significant investment, and all existing investors participated.[1] Isomorphic Labs said the proceeds would accelerate its scientific breakthroughs and proprietary AI advances.[2]

What the funding is meant to build

The company says it will use the funding to mature IsoDDE and expand into new biology with advanced models.[2] It is scaling both the proprietary drug-design engine and its AI-designed therapeutic-candidate pipeline.[2] Isomorphic Labs describes IsoDDE as combining foundational simulation AI models intended to work across therapeutic areas and drug modalities.[2] The company says the breadth and precision of those simulations push predictions toward experimental accuracy, and that the models are translating into advances across its multimodality candidate pipeline.[2]

Preclinical progress, not clinical results

Isomorphic Labs reported positive preclinical results in internal oncology and immunology programs, as well as in work with partners.[2] The company said those results were setting the stage for clinical entry.[2] Its stated aims for the round include building foundational biology models, deepening understanding of systemic disease and driving its first therapeutic programs toward clinical trials.[2] The evidence describes preclinical progress and plans for clinical entry; it does not say that a trial has begun or give clinical outcomes.[2]

Company context and partnerships

Isomorphic Labs was founded in 2021 to transform drug discovery using artificial intelligence, and is headquartered in London with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.[2] The company has struck deals with Eli Lilly, Novartis and Johnson & Johnson.[3] It says it is creating a partner ecosystem to advance understanding of mechanistic disease biology.[2] The funding came about six months after a $2.1 billion Series B, and the company declined to disclose its valuation.[4]

For life-sciences teams, the announcement points to continued investment in AI-based drug design alongside a pipeline that the company says is moving toward clinical entry. The reported results remain preclinical, so professionals assessing the technology should distinguish the company’s stated plans and early findings from demonstrated clinical outcomes.

Why it matters
For teams

AI training for your team

kju.ai is built for teams: daily sessions, team analytics, and rollout support for your organization.

How this developed

  1. 19 November 2026

    The evidence adds that Isomorphic Labs is scaling its therapeutic-candidate pipeline, aims to build foundational biology models and deepen systemic disease understanding, and describes repeatable model-enabled advances and a partner ecosystem.

  2. 19 November 2026

    Isomorphic Labs announces $5 billion Series C

Sources

AI fluency, one session a day, built for your work.